GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial

Capone, Stefania; Fusco, Francesco Maria; Milleri, Stefano; Borrè, Silvio; Carbonara, Sergio; Caputo, Sergio Lo; Leone, Sebastiano; Gori, Giovanni; Maggi, Paolo; Lichtner, Miriam; Cauda, Roberto; Zoppo, Sarah Dal; Cossu, Maria Vittoria; Gori, Andrea; Roda, Silvia; Confalonieri, Paola; Bonora, Stefano; Missale, Gabriele; Codeluppi, Mauro; Mezzaroma, Ivano; Capici, Serena; Pontali, Emanuele; Libanore, Marco; Diani, Augusta; Ippolito, Giuseppe; Battella, Simone; Contino, Alessandra Maria; Mortari, Eva Piano; Genova, F.; Parente, Gessica; Dragonetti, Rosella; Colloca, Stefano; Visani, Luigi; Iannacone, Claudio; Carsetti, Rita; Folgori, Antonella; Camerini, Roberto

doi:10.1016/j.xcrm.2023.101084

Cited by 3 publications

(3 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unvaccinated and vaccinated patients with at least two doses showed a median (IQR) time to negativity of 18 (17)(18)(19)(20)(21)(22) and 10 (7-13) days, respectively (Figures 1 and 2). Patients who did not receive early therapies reported a median (IQR) time to SARS-CoV-2 negativity of 14 days (9-17), whereas those treated with remdesivir, molnupiravir, nirmatrelvir/ritonavir 9 (7-12), 10 (7-14), and 10.5 (7)(8)(9)(10)(11)(12)(13)(14) days, respectively (Figures 3 and 4).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Vaccination and Antiviral Treatment Reduce the Time to Negative SARS-CoV-2 Swab: A Real-Life Study

De Vito,

Moi,

Saderi

et al. 2023

Viruses

View full text Add to dashboard Cite

Clinical trials demonstrated the role of vaccines and antiviral treatments against SARS-CoV-2 in reducing the likelihood of disease progression and death. However, there are limited data available regarding the time to negativity of people who received these treatments. Further, several comorbidities and risk factors might affect the impact of vaccines and antiviral treatments. To this end, we aimed to evaluate and disentangle the impact of anti-SARS-CoV-2 treatments and that of underlying clinical factors associated with a shortened length of SARS-CoV-2 infection. Hence, we recorded the timeframe of positive nasopharyngeal swab in people infected while being hospitalized for reasons other than SARS-CoV-2 infection. All patients who died or were discharged with a positive swab were excluded from the study. A total of 175 patients were included in this study. Clinical conditions encompass malignancies, immunological disorders, cardiovascular, metabolic, neurodegenerative, and chronic kidney disease. Most of the participants (91.4%) were vaccinated before admission to the hospital, and 65.1% received antiviral treatment within three days after the symptom’s onset. Unvaccinated patients had a longer median time to negativity than people who received at least two doses of vaccine (18 vs. 10 days). Concerning the clinical conditions of all patients, multivariate analysis highlighted a lower probability of 14-day conversion of antigenic test positivity in patients with hematological malignancy, including those vaccinated and those exposed to antiviral therapies. In conclusion, our data showed that prompt administration of antiviral treatments accelerates the clearance of SARS-CoV-2. Further, in the elderly patients under study, previous vaccination and antiviral treatment synergize to reduce time to negativity. This translates into a shorter hospitalization time and a lower risk of transmission through patients and connected healthcare workers in a hospital ward setting, with considerable improvement in cost-effective care management.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Studies demonstrated the efficacy of vaccines and antivirals in terms of reduction of disease progression and death [17][18][19]. However, poor information is available on the time length of negativization (TLN) in individuals exposed to antiviral drugs.…”

Section: Introductionmentioning

confidence: 99%

Vaccination and Antiviral Treatment Reduce the Time to Negative SARS-CoV-2 Swab: A Real-Life Study

De Vito,

Moi,

Saderi

et al. 2023

Viruses

View full text Add to dashboard Cite

show abstract

“…The condition spreads quickly, making many patients with underlying chronic liver disorders more vulnerable to infection. From a hepatology perspective, COVID-19 management and prevention are currently evolving as it is a relatively new illness [1][2][3].…”

Section: Introductionmentioning

confidence: 99%

Real-Life Experience in the Efficacy and Safety of COVID-19 Vaccination in Patients with Advanced Cirrhosis

Hanafy,

Embaby,

Salem

et al. 2023

JCM

View full text Add to dashboard Cite

COVID-19 infections accelerate liver decompensation and serious liver-related co-morbidities. The aim is to evaluate the safety and impact of COVID vaccines on hepatic disease progression in patients with advanced liver disease and to identify parameters that predict the occurrence of complications. The study involved 70 patients with advanced liver disease who were vaccinated with different COVID vaccines from January 2021 to April 2022. They were evaluated clinically. The laboratory investigation included a complete blood count, liver and kidney function tests, calculation of CTP and MELD scores, plasma levels of ammonia, abdominal ultrasound, and upper GI endoscopy. Twenty patients had experienced complications 64 ± 12 days from the last dose of a vaccination. Twenty patients (28.6%) developed hepatic decompensation and hypothyroidism (n = 11, 15.7%), and five (7.14%) patients developed splanchnic thrombosis. There were no COVID-19 reinfections except for two patients who received Sinopharm and developed vaccine-associated enhanced disease (2.9%). Complications after COVID vaccinations were correlated with ALT (r = 0.279, p = 0.019), serum sodium (r = −0.30, p = 0.005), creatinine (r = 0.303, p = 0.011), liver volume (LV) (r = −0.640, p = 0.000), and MELD score (r = 0.439, p = 0.000). Multivariate logistic regression revealed that LV is the only independent predictor (p = 0.001). LV ≤ 682.3 has a sensitivity of 95.24% and a specificity of 85.71% in predicting complications with an AUC of 0.935, p < 0.001. In conclusion, the hepatic reserve and prognosis in liver cirrhosis should be evaluated prior to COVID vaccinations using the MELD score and liver volume as promising risk stratification criteria. In summary, the research proposes a novel triaging strategy that involves utilizing the MELD score and liver volume as risk stratification parameters of the hepatic reserve and prognosis of advanced liver cirrhosis prior to COVID immunization to determine who should not receive a COVID vaccination.

show abstract

Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview

Henríquez,

Muñoz-Barroso

2024

Heliyon

View full text Add to dashboard Cite

GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial

Cited by 3 publications

References 58 publications

Vaccination and Antiviral Treatment Reduce the Time to Negative SARS-CoV-2 Swab: A Real-Life Study

Vaccination and Antiviral Treatment Reduce the Time to Negative SARS-CoV-2 Swab: A Real-Life Study

Real-Life Experience in the Efficacy and Safety of COVID-19 Vaccination in Patients with Advanced Cirrhosis

Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview

Contact Info

Product

Resources

About